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Background: The effect of small bowel transit time (SBTT) on diagnostic yield during capsule endoscopy (CE) has 
not been previously evaluated. Our study aim was to assess the effect of SBTT on the likelihood of detecting in-
testinal pathology during CE. Methods: We reviewed collected data on CE studies performed at Johns Hopkins 
Hospital from January 2006 to June 2007. In patients investigated for anemia or obscure bleeding, the following 
lesions were considered relevant: ulcers, erosions, AVMs, red spots, varices, vascular ectasias, and presence of 
blood. In patients with diarrhea or abdominal pain, ulcers, erosions, and blood were considered relevant. Age, 
gender, study indication, hospital status, and quality of bowel preparation were identified as candidate risk fac-
tors affecting SBTT. Univariate logistic and linear regression analyses were performed to study the effect of SBTT 
on diagnostic yield. Results: Total of 212 CE studies were analyzed; most were in outpatients (n=175, 82.9%) and 
with excellent bowel preparation (n=177, 83.5%). Mean SBTT was 237.0min (3.9hrs). Age, gender, bowel prep, 
hospital status, and study indication did not significantly affect SBTT. However, increased SBTT was independ-
ently associated with increased diagnostic yield; OR=1.7 in SBTT=2-4hr (p=0.41), OR=1.8 in SBTT=4-6hrs 
(p=0.30), OR=9.6 in SBTT=6-8hrs (p=0.05). Conclusion: Prolonged SBTT during CE (>6 hr) is associated with an 
increased diagnostic yield. This may be due to a positive effect on image quality during a “slower” study. The use 
of promotility agents may adversely affect the ability of CE to detect significant intestinal pathology. 
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INTRODUCTION 
Wireless capsule endoscopy (CE) was first de-
veloped for advanced imaging of the small intestine.1-3 
Although its clinical efficacy is most proven in the di-
agnosis of obscure gastrointestinal bleeding,4-6 it has 
also been helpful as an adjunct to radiological studies 
for patients with suspected Crohn’s disease, Celiac 
disease, small bowel tumors, anemia of unknown ori-
gin, chronic abdominal pain, and other indications.7-11 
The quality of a CE study for any given patient is 
largely dependent upon capsule transit time through 
the stomach and small intestine. Early reports showed 
that approximately 20% of patients undergoing CE 
had incomplete studies based on failure to visualize 
the cecum within the allotted lifetime of the battery 
pack.12-13 Delayed gastric emptying and small bowel 
dysmotility can both significantly affect the rate at 
which the capsule moves from stomach to cecum. In 
order to increase capsule transit speed, some have 
advocated the use of promotility agents such as 
erythromycin14  and metocloperamide15 just prior to 
capsule ingestion. Others have found, however, that 
use of such agents may adversely affect image quality 
within the small bowel.16  
The aim of our study was to assess the affect of 
small bowel transit time on the ability of CE to detect 
intestinal pathology in a large cohort of patients. The 
secondary aim was to identify candidate risk factors 
that may be used to predict capsule passage time 
through the small bowel. 
METHODS 
Consecutive patients undergoing CE without the Int. J. Med. Sci. 2008, 5 
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use of promotility agents at Johns Hopkins Hospital 
between January 2006 and June 2007 were reviewed 
for study. Permission to review patient records was 
granted by the Johns Hopkins University Institutional 
Review Board.  
All patients were asked to refrain from eating or 
drinking at least eight hours prior to swallowing the 
Given™ M2A video capsule endoscope (Given Imag-
ing Ltd., Yoqneam, Israel). Laxative bowel preparation 
was not used. Patients were allowed to eat and drink 
four hours after the start of their study. Each CE study 
was interpreted by one of five board-certified/board- 
eligible gastroenterologists (J.M.B., S.A.G., P.M., J.O.C., 
and E.Y.) using the RAPID 4™ software system (Given 
Imaging Ltd., Duluth, GA). All five readers had ex-
perience reviewing greater than 50 cases each. Images 
were reviewed with two or four simultaneous frames 
at a speed of 8-15 frames/second. All captured 
thumbnail images and summary reports were 
re-examined and verified by a separate, board-certified 
gastroenterologist (G.E.M.) with at least 500 cases of 
experience. The verifying physician used his discretion 
to re-examine certain segments of the CE study, or to 
review the entire study in total, pending the results or 
findings of the initial review. There was greater than 
95% concordance between the verifying reader 
(G.E.M.) and each of the five initial reviewers.  
Following each study, the interpreting physician 
was asked to record all endoscopic findings within a 
CE database. In those patients undergoing CE for the 
indications of obscure gastrointestinal bleeding or 
anemia of unknown origin, the following pathological 
lesions were considered relevant: ulcers, erosions, ar-
teriovenous malformations (AVMs), mucosal red 
spots, varices, venous ectasias, blood and blood clots. 
Red spots were defined as small, flat, pinpoint, red 
marks on the gastrointestinal mucosa believed to be a 
possible site of bleeding. AVMs were defined as larger 
red spots, or a confluence of mucosal spots, thought to 
represent a possible bleeding site. In all cases, if any 
one of the above lesions was detected, the study was 
marked as “positive” for significant findings. For those 
patients undergoing CE to investigate complaints of 
diarrhea or abdominal pain, the following lesions were 
considered relevant: ulcers, erosions, blood and blood 
clots. Again, if any one these findings was detected, the 
study yielded “positive” findings.  
Small bowel transit time was calculated for each 
study by subtracting the time of first duodenal image 
from the time of first cecal image on the Given™ 
software program. This value was recorded for each 
patient in minutes and then categorized into the fol-
lowing parameters: 0-2 hours (hrs), 2-4 hrs, 4-6 hrs, and 
6-8 hrs. All patients who experienced capsule failure in 
reaching the cecum or exiting the stomach in the al-
lotted eight hour study time were excluded from the 
analysis. The quality of the bowel preparation in each 
study was subjectively graded as poor, average, or 
excellent by the interpreting physician at the time of 
the initial read. Additional recorded variables in-
cluded physician reading time, patient gender, patient 
age (<40, 40-60, and >60 years), and inpatient versus 
outpatient status.  
Statistical analyses were performed using Stata 
9.0 (Stata Corp, College Station, Texas). Both univari-
ate logistic regression analysis and linear regression 
analysis were utilized. Identification of a positive (sig-
nificant) finding on CE was considered the main study 
outcome. The associations between small bowel transit 
time (SBTT) and positive CE findings were analyzed, 
and odds ratios (OR) with associated p-values and 95% 
confidence intervals (CI) were appropriately calcu-
lated. Additional covariates of patient age, gender, 
bowel preparation, and study indications were ana-
lyzed to detect positive associations with SBTT. Odds 
ratios with associated confidence intervals were again 
calculated; a p-value of ≤0.05 was considered statisti-
cally significant throughout.   
 
 
RESULTS 
Total of 212 patient CE recordings were studied 
between January 2006 and June 2007. Table 1 high-
lights the patient characteristics and study indications 
for each procedure. There were 88 males (41.5%) and 
124 females (58.5%) with a mean age of 51.8 years. 
Most CE studies (n=175, or 82.5%) were performed in 
outpatients, and most patients had an excellent bowel 
preparation (n=177, or 83.5%). When the total number 
of studies was divided according to clinical indication, 
the single most common indication was obscure GI 
bleeding (n=78, or 36.8%). The investigation of ab-
dominal pain was the second most common indication 
(n=54, or 25.5%), followed by anemia of unknown ori-
gin (n=42, or 19.8%) and diarrhea (n=38, or 17.9%).   
Small bowel transit time (SBTT) in the 212 pa-
tients undergoing CE is shown in Table 2. Mean pas-
sage time through the intestine was 239.0 minutes (3.9 
hrs), with a range between 19 and 480 minutes. Most 
patients (n=163, or 76.9%) recorded a SBTT of 120-240 
minutes (n=91) and 240-360 minutes (n=72). Total of 20 
patients (9.4%) had an exceptionally rapid SBTT of 
0-120 minutes, while 29 patients (13.7%) registered a 
delayed SBTT of 360-480 minutes. The average time for 
physician review of an entire CE study was 39.0 ± 10.2 
minutes. Int. J. Med. Sci. 2008, 5 
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Table 1. Demographics in 212 patients undergoing CE.  
Patient Characteristics  Mean ± SD,   
or Number (%) 
Age (yrs)  51.8 ± 16.0 
Males   88 (41.5) 
Females   124 (58.5) 
Inpatient 37  (17.4) 
Outpatient 175  (82.5) 
Bowel Prep   
 Excellent  177  (83.5) 
 Average  29  (13.7) 
 Poor  6  (2.8) 
Indication for CE    
  Obscure Bleeding  78 (36.8) 
  Abdominal Pain  54 (25.5) 
 Anemia  42  (19.8)   
 Diarrhea  38  (17.9) 
Table 2. Small bowel transit time (SBTT) in 212 patients un-
dergoing CE. 
Small Bowel Transit 
Time (SBTT) 
Mean ± SD, 
or Number (%) 
Average (min)  237.0 ± 91.8 
  
0-120 min  20 (9.4) 
120-240 min  91 (42.9) 
240-360 min  72 (34.0) 
360-480 min  29 (13.7) 
 
Table 3 shows the different pathological lesions 
identified in each patient undergoing CE. Overall, 
there were 181 lesions detected in 212 total patients. 
Mucosal red spots were the most common lesion rec-
ognized (56/181, or 30.9%), followed by mucosal ero-
sions (45/181, or 24.9%), AVMs (33/181, or 18.2%), 
ulcers (27/181, or 14.9%), venous ectasias (8/181, or 
4.4%), and intestinal varices (2/181, or 1.1%). There 
were 10 patients (5.5%) who had evidence of recent or 
ongoing intestinal bleeding without an obvious lesion 
seen during the study. These findings were considered 
relevant in those undergoing CE for any of the four 
indications.  
When the total number of CE findings was di-
vided according to indication for study, mucosal red 
spots were the most common finding in those patients 
investigated for obscure GI bleeding, abdominal pain, 
and anemia of unknown origin (Table 3). In patients 
with complaints of diarrhea, however, the most com-
mon lesion identified was an ulcer (40.9%). Mucosal 
erosions were the second most common lesion dis-
covered in studies performed for obscure GI bleeding, 
abdominal pain, and diarrhea; while AVMs were sec-
ond (27.8%) among patients with anemia of unknown 
origin.  
Table 4 summarizes the odds ratios (OR) with 
respective p-values for the association between small 
bowel transit time (SBTT) and reader detection of a 
positive finding during CE. Compared to patients with 
SBTT of 0-120 minutes (0-2 hrs), there was a weak as-
sociation between positive findings and SBTT of 
120-240 minutes (2-4 hrs) (OR=1.7, 95%CI=0.5-6.2, 
p=0.41) and 240-360 minutes (4-6 hrs) (OR=1.8, 
95%CI=0.5-6.6, p=0.30). Conversely, there was a 
stronger association between transit time and positive 
findings in those patients with SBTT of 360-480 min-
utes (6-8 hrs) (OR=9.6, 95%CI=1.9-10.5, p=0.05). This 
finding was statistically significant (Figure 1).  
Table 3. Pathological lesions found in 212 CE studies according 
to study indication. 
Type of 
Lesion 
 
 
Total (%)
(n=212) 
 
Obscure 
Bleeding 
(%) 
(n=78) 
Abdominal 
Pain (%) 
(n=54) 
Anemia 
(%) 
(n=42) 
Diarrhea 
(%) 
(n=38) 
Red Spots
 
56 (30.9)  20 (26.0)  16 (34.8)  14 (38.9)  6 (27.3) 
Erosions 
 
45 (24.9)  18 (23.4)  15 (32.6)  6 (16.7)  6 (27.3) 
AVMs 
 
33 (18.2)  15 (19.5)  7 (15.2)  10 (27.8)  1 (4.5) 
Ulcers 
 
27 (14.9)  11 (14.3)  5 (10.9)  2 (5.6)  9 (40.9) 
Varices 
 
2 (1.1)  2 (2.6)  0  0  0 
Venous 
Ectasias 
8 (4.4)  5 (6.5)  3 (6.5)  0  0 
Blood 
Clots or 
Bleeding 
10 (5.5)  6 (7.8)  0  4 (11.1)  0 
Total No. 
Lesions 
181 77  46  36  22 
 
Table 4. Association between SBTT and reader detection of a 
positive finding.  
Small Bowel 
Transit Time (SBTT) 
Odds Ratio 
(95% C.I.) 
p-value 
120-240 min  1.7 (0.5-6.2)  0.41 
240-360 min  1.8 (0.5-6.6)  0.30 
360-480 min  9.6 (1.9-10.5)  0.05 
 
 
 
 
Figure 1. Odds of detecting a positive finding during CE ac-
cording to small bowel transit time (x-axis). 
 Int. J. Med. Sci. 2008, 5 
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Table 5 outlines the results of analysis demon-
strating a lack of association between SBTT and patient 
age, gender, bowel preparation, hospital status, and 
indication for study. Compared to patients <40 years 
old (mean SBTT=242.4 min), average passage time 
through the small intestine was 237.3 and 229.8 min-
utes among patients 40-60 and >60 years old, respec-
tively (p=0.70, 0.50). In male patients, mean SBTT was 
only 3.9 minutes slower than female patients (235.1 
min vs. 231.2 min, p=0.71). There was a trend towards 
more rapid transit time in patients with a cleaner 
bowel preparation; that is, compared to patients with a 
poor bowel prep (SBTT=253.7 min), mean SBTT was 
240.6 and 237.5 minutes in those with an average and 
excellent prep, respectively (p=0.75, 0.67). Outpatients 
recorded a slightly faster transit time than inpatients 
undergoing CE (236.4 min vs. 241.5 min, p=0.61), but 
this difference was not significant. Finally, compared 
to those undergoing CE for anemia of unknown origin 
(mean SBTT=245.1 min), there were no statistically 
significant differences in SBTT for those in the obscure 
GI bleeding group (235.1 min, p=0.57), diarrhea group 
(225.6 min, p=0.35), or abdominal pain group (243.7 
min, p=0.94).  
Table 5. Association between small bowel transit time (SBTT) 
and age, gender, bowel preparation, hospital status, and indica-
tion for study. 
Patient Factors  SBTT (min)  p-value 
Age    
 <40  yrs  242.4  -- 
 40-60  yrs  237.3  0.70 
 >60  yrs  229.8  0.50 
Females 231.2  -- 
Males 235.1  0.71 
Bowel Preparation     
 Poor  253.7  -- 
 Average  240.6  0.75 
 Excellent  237.5  0.67 
Inpatients 241.5  -- 
Outpatients 236.4  0.61 
Indication for Study     
 Anemia  245.1  -- 
 Obscure  Bleeding  235.1  0.57 
 Diarrhea  225.6  0.35 
 Abdominal  Pain  243.7  0.94 
DISCUSSION 
Since the inception of capsule endoscopy (CE), it 
has been most frequently and most effectively utilized 
in the evaluation of obscure gastrointestinal bleed-
ing.18-19 More recently the indications have broadened 
with its usefulness demonstrated in the diagnosis of 
inflammatory bowel disease and the evaluation of 
chronic abdominal pain.7-11 The utility of a particular 
CE study, however, is largely dependent upon capsule 
transit time through the small intestine. Nearly 
one-fifth of patients experience capsule study fail-
ure;12-13 that is, lack of cecal visualization during the 
allotted study time. The reasons for an incomplete 
study are many, but some causes include delayed gas-
tric emptying, chronic intestinal dysmotility, small 
bowel strictures, and areas of intestinal diverticulosis 
promoting regional transit abnormalities.20 As a result, 
the use of promotility agents such as domperidone, 
erythromycin, metocloperamide, and even chewing 
gum have been advocated in order to decrease small 
bowel transit time, and thus diminish the likelihood of 
an incomplete study.14-15,17 At some centers, use of such 
agents prior to CE has become standard of practice; if 
not to prevent capsule failure, then to decrease overall 
study time and physician reader time.  
One potential problem with decreasing intestinal 
transit time during CE is impaired visualization of the 
entire small bowel mucosa. During most CE proce-
dures, the image quality in the proximal intestine is 
superior to that of the terminal ileum, mainly because 
of residual fecal material.16 Decreasing the gastric and 
small bowel emptying times with the use of promotil-
ity agents may, in effect, create poorer visualization as 
the capsule moves rapidly through the ileum or distal 
portions of intestine. In fact, Fireman et al studied 29 
patients receiving 200 mg of erythromycin 1 hour prior 
to capsule ingestion.16 They showed that image quality 
was significantly diminished compared to 40 patients 
that were not pretreated with erythromycin, and to 26 
patients that received polyethylene glycol (PEG) solu-
tion before the procedure. The reason for these find-
ings may be related to poorer image acquisition, and 
overall weaker bowel preparation, as the capsule en-
doscope moves rapidly through regions of retained 
intestinal fluid or residual fecal material. It is on this 
background in which we aimed to assess the affect of 
small bowel transit time (SBTT) on the ability of CE to 
detect significant intestinal pathology in a large cohort 
of patients. Furthermore, we aimed to identify certain 
risk factors that may help to predict either rapid or 
delayed capsule passage time through the small bowel.   
The results of our study suggest that a prolonged 
small bowel transit time during CE may be associated 
with a higher diagnostic yield. That is, in those patients 
that recorded an intestinal passage time of longer than 
six hours (average SBTT=3.9 hrs), the likelihood of 
detecting a positive finding was nearly 10 times 
greater than in those with a passage time under two 
hours (OR=9.6, 95%CI=1.9-10.5, p=0.05). Furthermore, 
patients with intestinal transit times between 2-4 hours 
and 4-6 hours were not associated with an increase in 
diagnostic yield (OR=1.7, p=0.41; OR=1.8, p=0.30 re-
spectively). In addition, after studying over 200 pa-
tients undergoing CE without bowel preparations or 
the use of promotility agents, we found there to be a Int. J. Med. Sci. 2008, 5 
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lack of association between small bowel transit time 
and patient age, gender, inpatient versus outpatient 
status, and the indication for the CE study. Lastly, we 
also demonstrated that the quality of a patient’s bowel 
preparation does not appear to have a significant effect 
on intestinal transit time in our large cohort of patients. 
How might a prolonged small bowel transit time 
be related to enhanced diagnostic yield during CE? 
Certainly one possibility is that the rate of intestinal 
transit may correspond with impaired motility in the 
context of small bowel pathology.21 In other words, 
intestinal peristalsis is reduced or diminished in the 
setting of a large mucosal ulceration or polypoid tu-
mor. This, in turn, accounts for the increased likeli-
hood of making a positive diagnosis in the presence of 
delayed intestinal emptying. On the other hand, the 
increase in diagnostic yield may be due to superior 
image acquisition or improvement in image quality as 
the capsule endoscope moves more slowly through 
areas of intestinal mucosa with discrete pathological 
lesions. In either case, a prolonged small bowel transit 
time appears to be associated with an increased chance 
of finding some form of pathology, thus arguing 
against the use of certain promotility agents to de-
crease CE procedure time, or to help prevent capsule 
failure.  
The main limitation of our study is its retrospec-
tive design. A large prospective study would be nec-
essary to verify our results, or provide further evi-
dence that strengthens the association between de-
layed intestinal transit and enhanced diagnostic yield. 
It is currently unknown as to whether or not even a 
repeat CE study in the same patient would produce a 
similar intestinal transit time as the initial study. In the 
future, it is likely that improvements in CE software 
systems or capsule endoscope design will mitigate 
some of these issues. For example, modification in 
image acquisition that varies according to the quality 
of a patient’s bowel preparation or the rate of intestinal 
transit would eliminate this problem, and thus more 
readily allow for the use of adjunctive promotility 
drugs. Likewise, a wider viewing angle on the camera 
itself, or improvements in software design that enable 
a greater number of images to be recorded and viewed, 
may also provide enhanced mucosal visualization and 
result in improved diagnostic capability, regardless of 
intestinal transit. Lastly, it is certainly within question 
as to whether or not the presence of mucosal red spots 
during CE represents truly relevant pathology. In our 
study, red spots were the most common lesion identi-
fied in patients undergoing CE for obscure GI bleeding 
and anemia of unknown origin; but from a clinician’s 
standpoint, it is often difficult to attribute such lesions 
to significant intestinal blood loss, and thus meaning-
ful pathology.  
Despite these limitations, it appears plausible to 
assume that rapid small bowel transit time may limit 
our detection capabilities in some patients undergoing 
CE. As such, the widespread, preemptive use of pro-
motility agents might contribute to this negative effect, 
and the use of such agents should be considered on a 
case-by-case basis. Furthermore, one may speculate 
that in patients with exceptionally rapid intestinal 
transit (e.g. <2 hrs), use of anticholinergics or other 
motility-delaying agents would provide a more com-
plete study with maximum mucosal detection; at least 
until improvements in the current versions of the 
capsule endoscope and software system allow us to 
overcome this issue. 
In conclusion, our retrospective study demon-
strated that a prolonged small bowel transit time (>6 
hrs) during CE may be associated with an increased 
diagnostic yield. This finding does not appear to be 
related to other factors such as the quality of the bowel 
preparation, patient age or gender, inpatient versus 
outpatient status, or indication for the study. There 
may be a positive effect on image quality during a 
“slower” study, thereby suggesting the use of promo-
tility agents adversely affects the ability of CE to detect 
significant intestinal pathology.   
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